Royalty Pharma director awarded 689 shares

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an award of 689 Class A Ordinary Shares, valued at $54.3998 per share. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a quarterly cash retainer of $37,500.

After this equity award, Bassler directly holds 79,181 Class A Ordinary Shares. This transaction reflects compensation paid in stock rather than cash, and does not represent an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 689 shares

Grant/Award 1 txn

Insider Bassler Bonnie L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	689	$54.3998	$37K

Holdings After Transaction: Class A Ordinary Shares — 79,181 shares (Direct)

Footnotes (1)

1. F1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

Key Figures

Shares granted: 689 shares Grant price per share: $54.3998 per share Quarterly retainer value: $37,500 +1 more

4 metrics

Shares granted 689 shares Class A Ordinary Shares awarded as director compensation

Grant price per share $54.3998 per share Valuation used for the equity award

Quarterly retainer value $37,500 Director retainer paid in shares instead of cash

Shares held after transaction 79,181 shares Bassler’s direct Class A Ordinary Share holdings after award

Key Terms

Class A Ordinary Shares, 2020 Independent Director Equity Incentive Plan, quarterly retainer payment

3 terms

Class A Ordinary Shares financial

"Reflects Class A Ordinary Shares issued to the reporting person"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

2020 Independent Director Equity Incentive Plan financial

"issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan"

quarterly retainer payment financial

"in lieu of a quarterly retainer payment of $37,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Royalty Pharma (RPRX) director Bonnie L. Bassler receive in this transaction?

Bonnie L. Bassler received 689 Class A Ordinary Shares of Royalty Pharma as an equity award. The shares were granted as director compensation under the 2020 Independent Director Equity Incentive Plan, replacing a portion of her normal cash retainer for the quarter.

At what price were the Royalty Pharma (RPRX) shares valued in Bassler’s grant?

The 689 Class A Ordinary Shares granted to Bonnie L. Bassler were valued at $54.3998 per share. This per-share value is used to translate her $37,500 quarterly retainer into an equivalent stock-based compensation amount under the director equity plan.

How many Royalty Pharma (RPRX) shares does Bonnie L. Bassler hold after this award?

Following the equity award, Bonnie L. Bassler directly holds 79,181 Class A Ordinary Shares of Royalty Pharma. This figure includes the newly granted 689 shares issued in lieu of her $37,500 quarterly retainer under the 2020 Independent Director Equity Incentive Plan.

Was cash paid to Bonnie L. Bassler by Royalty Pharma (RPRX) in this transaction?

No cash was paid in this transaction; instead, Bassler received shares in lieu of a $37,500 quarterly retainer. The Class A Ordinary Shares were issued under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan as non-cash director compensation.

Is this Royalty Pharma (RPRX) transaction an open-market stock purchase or sale?

This transaction is not an open-market stock purchase or sale. It is a grant of 689 Class A Ordinary Shares to director Bonnie L. Bassler as equity compensation in place of a $37,500 quarterly retainer under the 2020 Independent Director Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bassler Bonnie L

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/30/2026		A		689	A	$54.3998(1)	79,181	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Bonnie L. Bassler	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)